UNSPSC 51281604: Arbekacin

This classification denotes an aminoglycoside antibiotic with the molecular formula C22H44N6O10, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier G7V6SLI20L, chemically known as o-3-amino-3-deoxy-alpha-d-glucopyranosyl-(1->4)-o-(2,6-diamino-2,3,4,6-tetradeoxy-alpha-d-erythro-hexopyranosyl-(1->6))-n-((2s)-4-amino-2-hydroxybutyryl)-2-deoxy-l-streptamine but generally known as arbekacin, which bears US NIH Compound Identifier 68682. Arbekacin most often comes in base and sulfate forms.

UNSPSC 51281604 Arbekacin, a Commodity code, nominally covers the aminoglycoside antibiotic arbekacin; however, recent state and local procurement activity under this code does not reflect arbekacin purchases. Instead, the code appears to be used by state health departments and county agencies to tag pharmaceutical supply contracts for other medications and medical products. The Illinois Department of Public Health awarded a piggyback pharmaceutical warehouse contract through the MMCAP cooperative purchasing vehicle to supply Doxycycline Hyclate 100mg tablets and Ciprofloxacin Hydrochloride 500mg tablets, while Seminole County, Florida sought competitive bids for Naloxone and Safe Drug Deactivation Systems. Both procurements reflect state and local governments' use of cooperative purchasing and direct procurement vehicles to source pharmaceuticals and emergency medical supplies through fixed-term contracts with renewal options.

Activity appears concentrated in Florida and Illinois based on recent opportunities. The Illinois Department of Public Health awarded a $2,999,999.11 three-year piggyback contract (including renewal periods) for antibiotic tablets through an Invitation for Bid process; the contract went to Chartwell Rx LLC as the lowest priced responsive and responsible bidder with an August 28, 2026 award date. Seminole County, Florida released an IFB on June 30, 2026 for 1,900 units of Naloxone and 800 Safe Drug Deactivation Systems annually with quarterly deliveries, a July 26, 2023 response deadline (note: deadline predates posting), an initial two-year term with a one-year renewal option, and FEMA funding involvement. The mismatch between the code's nominal scope (arbekacin) and actual recent procurements (doxycycline, ciprofloxacin, naloxone, deactivation systems) signals either miscoding or category drift in how state and local agencies tag pharmaceutical supply orders.